Open AccessIn-silico Druggability Studies of 4-hydroxy-α-tetralone and its Derivatives with RND Efflux pump of E. coli
Author(s) -
Sonam Singh,
A. Swaroop Sanket,
Gaurav Raj Dwivedi,
Harish C. Upadhyay
Publication year - 2020
Publication title -
pharmaceutical and biosciences journal
Language(s) - English
Resource type - Journals
ISSN - 2582-0540
DOI - 10.20510/ukjpb/8/i2/1586224632
Subject(s) - efflux , tetracycline , chemistry , in silico , multiple drug resistance , docking (animal) , multidrug resistance associated proteins , druggability , pharmacology , antibiotics , biochemistry , stereochemistry , combinatorial chemistry , biology , atp binding cassette transporter , transporter , medicine , nursing , gene
The compound 4-hydroxy-α-tetralone (1) has been reported to possess potent anti-tubercular, anti-diabetic and anti-leishmanial activities. In our earlier studies the compound 1 and its various semi-synthetic derivatives showed potent bioenhancing activity in combination with nalidixic acid (NAL) and tetracycline (TET) reducing the minimum inhibitory concentration (MIC) of antibiotics up to 8 folds by inhibition of ABC efflux pump. However, in gram negative bacteria, resistance nodulation division (RND) family are considered as major efflux pump responsible for multidrug resistance (MDR). Hence, the current study was carried out to access the in-silico docking potential of compound 1 and its cinnamoyl (1a), 3, 4, 5-trimethoxybenzoyl (1b) derivatives against RND efflux pump target proteins AcrA, AcrB, TolC of E. coli. The docking study showed that the test compounds have good binding affinity with target proteins. The derivative 1a showed highest interaction with AcrA followed by AcrB showing binding energies -8.7 and -8.2 kcal/mol respectively. The low molecular weight ≤500, high hydrogen bonding, high log p value (>1) with hydroxy, methoxy and aromatic group of ligands make these compounds as effective efflux pump inhibitor. In drug likeliness studies, these compounds pass the safety criteria with enhanced bioavailability and absorption, less acute oral toxicity, less hepatotoxicity. This study promises that the compound 1 and its derivatives (1a & 1b) might be RND efflux pump inhibitors providing the initial platform for development of safer and cost-effective antibacterial drug to manage MDR infections.